Quick Answer
AGIOS PHARMACEUTICALS, INC. reported Diluted EPS of $7.12 per share (loss) for fiscal year 2025.
AGIOS PHARMACEUTICALS, INC. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$7.12 | -161.2% |
| 2024 | $11.64 | +283.9% |
| 2023 | -$6.33 | -49.6% |
| 2022 | -$4.23 | -115.9% |
| 2021 | $26.55 | +660.1% |
| 2020 | -$4.74 | +30.9% |
| 2019 | -$6.86 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$1.78 | -111.0% | +7.8% |
| June 30, 2025 | -$1.93 | -14.2% | -24.5% |
| March 31, 2025 | -$1.55 | -6.9% | -109.6% |
| September 30, 2024 | $16.22 | +1089.0% | +1059.8% |
| June 30, 2024 | -$1.69 | -11.9% | -16.6% |
| March 31, 2024 | -$1.45 | +1.4% | +11.6% |
| September 30, 2023 | -$1.64 | -10.1% | -8.6% |
| June 30, 2023 | -$1.51 | +10.1% | -2.7% |
- AGIOS PHARMACEUTICALS, INC. showed a decrease of -161.2% in Diluted EPS compared to the prior fiscal year.
- Over the 2019–2025 period, AGIOS PHARMACEUTICALS, INC.’s diluted eps has declined by 3.8% (from $6.86 per share (loss) to $7.12 per share (loss)).
- The most recent figure is from AGIOS PHARMACEUTICALS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: